POPULATION SCREENING FOR CHRONIC DISEASE MAXIMISING BENEFITS, MINIMISING HARMS Public Health Association of Australia (PHAA) hold conference on current and future advances in population screening
With
Adjunct Professor Terry Slevin, Chief Executive Officer
Public Health Association of Australia
Australian Health Journal Segment
Filmed in Sydney | March 2025
Population screening is an important contributor to advancing health outcomes through the early detection of and successful intervention for chronic disease. The evolution of science, technology and evidence relating to diseases which are or may be amenable to a population screening approach deserve broad discussion and the sharing of expertise and evidence. They also warrant close scrutiny in context of health policy and health resource allocation considerations.
There are established (and proposed) screening programs relevant to a range of diseases, notably breast, cervix, bowel cancer, and more recently for skin and lung cancer screening. There are a number of other chronic diseases where as new technologies are emerging and evidence is being gathered to support organised screening, (including but not limited to diabetes, CKD, MAFLD as well as cardiovascular and other risk assessment for primary prevention in general practice.
Population-based criteria for screening, based on WHO criteria and the Australian Population Based Screening Framework, aim to ensure that the benefits of screening outweigh and minimise any potential harms. These criteria are well understood by those involved in established screening programs and advocates for emerging screening programs are keen to learn from past experience how to compile evidence, design, implement and monitor programs, as well as ensure equitable participation. Similarly, there is much to learn from emerging programs and new technologies for those involved in established programs where adopting advances in evidence and technology can be challenging and perceived as slower.
In March, Public Health Association of Australia (PHAA) convened Screening Conference Conference 2025 with the theme of ‘Population Screening for Chronic Disease – Maximising Benefits, Minimising Harms’.
The conference provided opportunities for attendees to exchange information on population screening and learn from each other’s experience, across a range of disciplines. Those in attendance and presenting came from research, society, Government, program delivery, policy, consumers and clinicians.
Source: Adapted from Screening 2025 Conference website (PHAA operated)
-
Recognising service in health regulation
In April 2023, Professor John Skerritt retired from his position of Deputy Secretary Health Products Regulation Group, a role he has been in since 2012. During his time at the TGA he had line responsibility for over 1200 staff involved in the regulation of therapeutic goods, regulation of gene technology and industrial chemicals and control of drug import, export and production.
At this year’s ARCS 2023 Conference, ARCS Australia CEO Dr Shanny Dyer paid tribute to Professor Skerritt and his service to the Australian health industry. She led a tribute with fellow industry heads, Elizabeth de Somer, CEO, Medicines Australia, Anne Harris, Managing Director, Pfizer Australia & New Zealand, Deon Schoombie, CEO, Consumer Healthcare Products Australia, Ian Burgess, CEO, Medical Technology Association of Australia and Arthur Brandwood, President ARCS Australia.
-
World first in rural and remote nursing
In March 2023, the Australian Government released the National Rural and Remote Nursing Generalist Framework 2023–2027. The Framework is a world first and describes the unique context of practice and core capabilities for rural and remote Registered Nurses in Australia.
The Framework was developed by the Office of the National Rural Health Commissioner and Australian Health Journal spoke with National Rural Health Commissioner, Adjunct Professor Ruth Stewart, and Deputy National Rural Health Commissioner – Nursing and Midwifery, Adjunct Professor Shelley Nowlan, on the importance of rural and remote nursing and of the Framework itself.
-
Reflecting on a pivotal year for pharmacy
Dr. Kate Wang, a Senior Lecturer in Pharmacy at RMIT University and Adjunct Senior Lecturer, University of Western Australia, has over a decade of experience in both hospital and community pharmacy settings.
Dr Wang spoke to Australian Health Journal on some of the key topics in 2024 that have been pivotal as a pharmacist, academic and researcher for the pharmacy profession.
